AI-generated analysis
Coller Capital's acquisition of Pharmacy2U through a continuation fund serves to address a significant capital structure challenge in private equity by providing liquidity to existing investors while maintaining control over a high-growth asset. This strategic move ensures that Pharmacy2U, a leading U.K.-based online pharmacy, can continue its expansion and innovation efforts without the constraints often associated with traditional exit strategies for PE firms. The £500 million ($669m) continuation fund allows Coller Capital to retain ownership and facilitate reinvestment in Pharmacy2U’s next phase of growth, positioning it as a long-term strategic partner rather than a short-term investor.
The transaction mechanics involve the creation of a bespoke continuation vehicle managed by G Square Healthcare Private Equity LLP. This structure enables existing shareholders and institutional investors to realize value while simultaneously injecting new capital into Pharmacy2U for continued development. The valuation multiple is not disclosed, but given the significant size of the deal and Pharmacy2U’s market leadership position, it likely reflects a premium based on the company's growth prospects.
From a competitive perspective, this deal shifts dynamics within the European health-tech sector by reinforcing Pharmacy2U's dominant position in online pharmacy services. With enhanced financial backing, Pharmacy2U can accelerate its technological advancements and expand its service offerings, potentially increasing market share at the expense of competitors. Additionally, the continuation fund model may inspire other firms to explore similar structures for their portfolio companies, driving broader changes in how PE-backed entities manage liquidity needs.
Looking ahead, key risks and integration challenges will center around maintaining Pharmacy2U’s rapid growth trajectory while managing increased expectations from its new investor base. The company must also navigate regulatory scrutiny as it expands its digital health services. However, the deal creates a strong foundation for sustainable long-term growth by aligning interests between investors and management, enabling greater focus on strategic initiatives such as scaling operations and investing in emerging technologies within healthcare delivery.
Coller Capital has acquired Pharmacy2U, establishing a continuation vehicle to provide liquidity to existing investors while enabling future investment in the company's growth. The deal closed on July 10, 2026, with a value of $669 million and involved sell-side advice from Lazard and legal counsel from Goodwin Procter and Proskauer Rose for Pharmacy2U.
| Acquirer | Coller Capital (GB) |
|---|
| Target | Pharmacy2U (GB) |
|---|
| Type of deal | Continuation Vehicle |
|---|
| Deal value ($M) | $669m |
|---|
| Closing date | 2026-07-10 |
|---|
| Sell-side advisor | Lazard |
|---|
| Legal (buy side) | Akin Gump |
|---|
| Legal (sell side) | Goodwin Procter, Proskauer Rose |
|---|
Deal mechanics
The deal was structured as a continuation vehicle to provide liquidity to existing investors in Pharmacy2U. Coller Capital, acting as the sole lead investor, will enable Pharmacy2U's continued expansion and investment in its next growth phase.
Strategic rationale
The acquisition aims to unlock value for shareholders while maintaining the operational independence of Pharmacy2U. By creating a continuation vehicle, Coller Capital can continue to support Pharmacy2U’s strategic initiatives, particularly focusing on its pharmacy and health services in the UK market.
Financial context
With the deal valued at $669 million, this represents a significant milestone for Pharmacy2U. The company will leverage the liquidity from Coller Capital to fund further expansion and improve its service offerings. Additionally, it provides an opportunity for existing shareholders to realize value while retaining exposure to Pharmacy2U’s future prospects.
Advisors
Sell-side advisory services were provided by Lazard, with legal counsel coming from Goodwin Procter and Proskauer Rose on behalf of Pharmacy2U. The buy-side was advised by Akin Gump. Specific key terms of the deal were not disclosed.
Outlook
This continuation vehicle is expected to be a catalyst for sustained growth at Pharmacy2U, positioning it as a leader in digital healthcare services. The transaction underscores the strategic importance of providing liquidity solutions while fostering innovation and market leadership.